LENZ Therapeutics (LENZ) Financials

LENZ Therapeutics’ Q1 2026 results show a company still in heavy pre-commercial spending mode, with meaningful cash resources but ongoing large losses and negative operating cash flow.

Revenue in the quarter was just $1.9 million, while operating expenses totaled $45.0 million, driven almost entirely by SG&A of $45.0 million. That produced an operating loss of $44.1 million and a net loss of $41.5 million, or $1.32 per share.

Cash flow remained negative from operations, with operating cash burn of $33.6 million in the quarter. However, LENZ offset that with a large inflow from investing activities, as maturities and sales of investments brought in more cash than was deployed into new investments. The company also ended the quarter with a strong balance sheet, including $24.8 million in cash and $233.6 million in short-term investments.

Compared with prior quarters, the business appears to have moved from a financing-heavy, development-stage profile toward one supported by its existing cash and investment portfolio. Still, the key challenge is clear: the company is burning significant cash while generating only modest revenue.

• Large cash and investment cushion: LENZ ended Q1 2026 with $258.4 million combined in cash and short-term investments, giving it substantial liquidity.
• Balance sheet remains strong: Total assets were $272.5 million versus only $26.0 million in total liabilities, leaving a very clean leverage profile.
• Minimal debt burden: The company reported only $237,000 in noncurrent liabilities, suggesting limited balance sheet risk from borrowings.
• Operating asset/liability changes helped cash flow: Working capital movements contributed $3.4 million in Q1 2026, partially easing the burn.
• Revenue is present but still very small: Quarterly revenue of $1.9 million is improving the topline, but it remains far too small to cover operating costs.
• Investment income helps offset losses: LENZ generated $2.6 million of interest and investment income in Q1 2026, which provided some support to pre-tax results.
• Share count was fairly stable sequentially: Weighted average diluted shares were 31.35 million in Q1 2026 versus 31.35 million in Q4 2025, limiting near-term dilution concerns in the quarter.
• Operating losses remain very large: Q1 2026 operating loss was $44.1 million, showing the business is still far from operating breakeven.
• Cash burn is still high: Operating cash outflow of $33.6 million indicates the company continues to consume capital quickly.
• Expenses surged versus revenue: SG&A expense of $45.0 million dwarfed revenue, highlighting the current commercialization and development cost structure.

Looking at the broader trend since 2023, LENZ has gone through a major evolution in its capital structure. In 2023, the company held far more cash and investments and also recorded large equity issuance activity. Since then, the balance sheet has become more streamlined, but losses have continued as the company advances its development and commercialization efforts. For investors, the main question is whether LENZ can turn current spending into a much larger revenue base before its cash runway becomes a concern.